Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02446444 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

Study acronym: ENZARAD
StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated May 6, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Jun 2025 to Jun 2026
    • Study completion date: Mar 2026 to Jun 2026
    v22
  2. Primary completion date: Dec 2024 to Jun 2025
    • Study completion date: Dec 2025 to Mar 2026
    v21
  3. Re-verified, no change to tracked fieldsv20
  4. Primary completion date: Dec 2023 to Dec 2024
    • Study completion date: Jul 2024 to Dec 2025
    • Study sites revised (69)
    v19
  5. Primary completion date: Sep 2021 to Dec 2023
    • Study completion date: Dec 2021 to Jul 2024
    v18
Show 16 earlier versionsHide 16 earlier versions
  1. Primary endpoint revisedv17 Show 4 more changesShow less
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints revised (9)
    • Study sites revised (69)
    • Collaborators: 4 to 5
  2. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 800 to confirmed 802
    • Study sites: 70 to 69
    v16
  3. Study sites: 65 to 70v15
  4. Study sites: 64 to 65v14
  5. Site contacts updated at 2 of 64 sitesv13
  6. Site details revised at 4 of 64 sitesv12
  7. Study sites: 56 to 64v11
  8. Re-verified, no change to tracked fieldsv10
  9. Study sites: 48 to 56v9
  10. Study sites: 47 to 48v8
  11. Study sites: 46 to 47v7
  12. Study sites: 45 to 46v6
  13. Study sites: 44 to 45v5
  14. Study sites: 31 to 44
    • Interventions: Conventional NSAA (Drug), Enzalutamide (Drug), External Beam Radiotherapy (78 Gy in 39 fractions) (Radiation), LHRHA (Drug) to Conventional NSAA (Drug), Enzalutamide (Drug), External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus…
    • Eligibility criteria expanded, about 32 words
    • Secondary endpoints: 7 to 9
    v4
  15. Site details revised at 1 of 31 sitesv3
  16. Secondary endpoints revised (7)v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to determine the effectiveness of enzalutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinizing hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at high risk of recurrence.
Trial Details
NCT Number NCT02446444
Lead Sponsor University of Sydney
Collaborators: Australian and New Zealand Urogenital and Prostate Cancer Trials Group, National Health and Medical Research Council, Australia, Cancer Trials Ireland, Trans Tasman Radiation Oncology Group, European Organisation for Research and Treatment of Cancer - EORTC
Conditions
(from sponsor)		 Prostatic Neoplasms
Related terms Prostatic Neoplasms
Enrollment 802 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov